Clinical Trials
12 trialsNCT07287150 2026-06-04
InavoPC
Hoffmann-La Roche
Phase 2 Recruiting
NCT07618390 2026-06-01
A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07054190 2026-05-26
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT07405801 2026-05-18
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT07368998 2026-05-11
optINAVO
Hoffmann-La Roche
Phase 2 Recruiting
NCT04589845 2026-05-08
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT07522697 2026-04-13
MITO END-4
National Cancer Institute, Naples
Phase 2 Not yet recruiting
NCT04931342 2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05708235 2026-03-05
MiRaDoR
MedSIR
Phase 2 Recruiting
NCT07441512 2026-03-02
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
NCT07245797 2025-11-24
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC
Fudan University
Phase 2 Not yet recruiting